trending Market Intelligence /marketintelligence/en/news-insights/trending/0056OOFRXywQhTrSLk_0hw2 content esgSubNav
In This List

Nymox reports positive phase 3 trial results for prostate cancer drug


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Nymox reports positive phase 3 trial results for prostate cancer drug

Nymox Pharmaceutical Corp. reported statistically significant results from phase 3 trials of fexapotide triflutate to treat prostate enlargement and prostate cancer.

According to the results, patients treated with the drug exhibited indications of sexual function improvement.

The first-line previous treatment-naive patients showed statistically significant improvements from baseline compared to the lack of improvements in the placebo group one year after treatment.

Fexapotide-treated subjects had statistically significant improvement compared to placebo, while placebo-treated patients also experienced worsening of sexual function.

Nymox initially reported the absence of significant sexual or other side-effects from the drug based on 15 years of clinical research in prospective randomized trials in the U.S.

The company submitted a marketing approval application in Europe for the drug May 3.